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Abstract
 
The combination of hemorrhagic pneumonitis and rapidly progressive glomerulonephritis is a
characteristic feature of Goodpasture’s syndrome (GPS), an autoimmune disease resulting from
the interaction of pathogenic anti–collagen type IV (C-IV) antibodies with alveolar and glom-
erular basement membranes. Lack of a suitable animal model for this fatal disease has hampered
 
both a basic understanding of its etiology and the development of therapeutic strategies. We now
report a novel model for GPS using mice deficient in a central regulatory receptor for immuno-
 
globulin (Ig)G antibody expression and function, the type IIB Fc receptor for IgG (Fc
 
g
 
RIIB).
Mutant mice immunized with bovine C-IV reproducibly develop massive pulmonary hemor-
rhage with neutrophil and macrophage infiltration and crescentic glomerulonephritis. The dis-
tinctive linear, ribbon-like deposition of IgG immune complex seen in GPS was observed
along the glomerular and tubulointerstitial membranes of diseased animals. These results high-
 
light the role of Fc
 
g
 
RIIB in maintaining tolerance and suggest that it may play a role in the
pathogenesis of human GPS.
Key words: Goodpasture’s syndrome • type IV collagen • Fc receptor • autoimmunity • 
alveolar/glomerular basement membrane
 
Introduction
 
Patients with Goodpasture’s syndrome (GPS) display a
characteristic rapid and progressive glomerulonephritis and
hemorrhagic pneumonitis with often fatal results (1–3).
The presence of anti–collagen type IV (C-IV) antibodies
and the characteristic ribbon pattern of immune complex
deposition along the basement membranes of both lung
and glomeruli has lead to a proposed pathogenic model for
this disease (4–6). Autoantibodies to common components
of the basement membranes of these two organs develop,
notably to the 
 
a
 
3 domain of C-IV, are deposited (7), and
trigger effector cell activation and inflammatory sequelae.
The mechanism(s) that result in the loss of tolerance and
the development of autoantibodies to C-IV are unknown.
Investigations into the proposed pathogenesis of this disease
and development of therapeutic strategies have been ham-
pered by the lack of a suitable animal model. Attempts to
develop such a model for GPS by immunizing sheep (8) or
rats (9, 10) with homologous or heterologous glomerular
basement membrane preparations have resulted in only par-
tial success. For example, Abate et al. (10) induced glomeru-
lonephritis and hemorrhagic pneumonitis in Wistar-Kyoto
rats by immunization with the 
 
a
 
3 chain of C-IV, but the
observed lesions were only marginal. Similarly, injecting
anti–glomerular basement membrane antibody into mice
or their immunization with recombinant protein for the
NC1 domain of the 
 
a
 
3 chain of C-IV resulted in little or
only marginal alveolar hemorrhage, in spite of the develop-
ment of glomerular disease (11). These studies support the
conclusion that immunization with C-IV alone is insuffi-
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cient to trigger the full spectrum of GPS, thus pointing to
the contribution of additional susceptibility factors neces-
sary to the development of full-blown disease.
We have previously shown that Fc
 
g
 
RIIB-deficient
(Fc
 
g
 
RIIB
 
2
 
/
 
2
 
) mice of the H-2
 
b
 
 haplotype are susceptible
to type II collagen–induced arthritis (12), a model for rheu-
matoid arthritis in humans, which previously could only be
induced in susceptible rodents of particular MHC haplo-
types, specifically H-2
 
q
 
 or H-2
 
r
 
 in mice. The etiology of the
arthritis seen in these Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 animals could be attrib-
uted to the enhanced humoral immune response to type II
collagen and augmented proinflammatory mediator release
by effector cells such as macrophages (12). The inhibitory Fc
receptor for IgG immune complexes, Fc
 
g
 
RIIB, plays a cen-
tral role in both the afferent and efferent limbs of the im-
mune response, shaping the antibody repertoire, maintaining
peripheral tolerance, and setting thresholds for effector cell
activation. Animals deficient in this receptor have general-
ized enhanced antibody responses (13) and heightened in-
flammation in all antibody-mediated classes of hypersensitiv-
ity reactions (12, 14). These observations prompted us to test
whether Fc
 
g
 
RIIB may regulate responses to C-IV and be a
critical factor in GPS development. Our data indicate that
immunization of Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 animals with C-IV results in
autoimmunity and culminates in GPS-like disease, suggest-
ing a role for the Fc
 
g
 
RIIB regulatory pathway in the etiol-
ogy of this autoimmune disease.
 
Materials and Methods
 
Animals.
 
Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 mice were generated in the 129/SvJ
(H-2
 
b
 
) and C57BL/6 (B6, H-2
 
b
 
) hybrid background as described
previously (13). FcR
 
g
 
2
 
/
 
2
 
 mice (15) were backcrossed to B6 mice
over six generations. These mice and their wild-type counterparts
(129/B6 hybrids and B6 mice for Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 and FcR
 
g
 
2
 
/
 
2
 
, re-
spectively) were kept and bred in the Animal Unit of The Insti-
tute of Development, Aging and Cancer (Tohoku University, Ja-
pan), an environmentally controlled and specific pathogen–free
facility. B6 mice were obtained from Charles River Labs. Japan,
Inc. All experiments were performed on 8-wk-old male and fe-
male mice.
 
C-IV Immunization.
 
Bovine C-IV (Cellmatrix IV
 
®
 
) was ob-
tained from Nitta Gellatin, Inc. The C-IV solution (3.0 mg/ml in
1 mM HCl, pH 3.0) was neutralized by adding 1 mM NaOH (fi-
nal concentration) before emulsifying with Freund’s adjuvant. Mice
were immunized at the tail base with 150 
 
m
 
g of C-IV emulsified in
CFA containing 
 
Mycobacterium tuberculosis
 
 strain H
 
37
 
Rv (Wako
Pure Chemical Industries, Ltd.) and boosted at the same location
with 150 
 
m
 
g of C-IV plus IFA (Wako Pure Chemical Industries,
Ltd.) 2, 4, and 6 wk later. The mice were killed 56 d later and
processed for histopathological examinations.
 
Assay for Detection of Serum Anti–C-IV Antibodies.
 
Blood was
collected from the subocular plexus of mice into microcentrifuge
tubes containing EDTA on ice, and plasma was prepared. Serum
antibody titers were measured by ELISA. Antibodies to bovine
C-IV were detected in a 96-well microplate assay (Falcon; Bec-
ton Dickinson Labware) in which wells were coated with 50 
 
m
 
l/
well of a 20 
 
m
 
g/ml solution of bovine C-IV in PBS at 4
 
8
 
C for
overnight, washed three times with PBS containing 0.05%
Tween 20 and 0.1% BSA, and then blocked with 250 
 
m
 
l/well of
 
PBS containing 0.2% BSA at 4
 
8
 
C for overnight. Antibodies to
mouse C-IV were detected by the use of the BIOCOAT
 
®
 
 cellware
mouse C-IV 96-well plate assay (Becton Dickinson Labware). The
diluted serum (1:2,500–5,000) was added at 50 
 
m
 
l/well and al-
lowed to react overnight at 4
 
8
 
C. The wells were washed three
times with PBS containing 0.05% Tween 20, incubated with 50 
 
m
 
l
of a 1:200 dilution of goat anti–mouse IgG1, IgG2a, IgG2b, IgM,
or IgA coupled to horseradish peroxidase (Sigma Chemical Co.) at
4
 
8
 
C for 2 h, washed three times with PBS containing 0.05%
Tween 20, and developed at room temperature for 30 min with
0.1 ml of TrueBlue Peroxidase Substrate (Kirkegaard & Perry
Labs.). The OD at 450 nm was read using a Biolumin960 Micro-
plate Reader (Molecular Dynamics Japan, Inc.).
 
Evaluation of Renal Functions.
 
Serum samples at 56 d were in-
spected for blood urea nitrogen (BUN) and serum creatinine (Cr)
levels by the urease GLDH-UV method and ELISA using a
TOSHIBA TBA-80FR. Proteinuria was monitored by the tetra-
bromophenol blue reaction assay using the Micro AUTION
MA-4260 (Kyoto Daiichi Kagaku Co.).
 
Histological Study and Immunohistochemistry.
 
Mice were killed
by cervical dislocation at day 56. Their lungs and kidneys were
removed and fixed in 10% (vol/vol) neutral buffered formalin,
followed by embedding in paraffin. The lung specimens were
sectioned at 5 
 
m
 
m and stained with hematoxylin and eosin or pe-
riodic acid-Shiff (PAS). The kidney sections were stained with
PAS. Alternatively, formalin-fixed and paraffin-embedded lung
and kidney section (5 
 
m
 
m) were deparaffinized in xylen and re-
hydrated through graded ethanols. After washing with distilled
water, sections were incubated in PBS containing STUF (Serotec
Target Unmasking Fluid; Serotec Ltd.) for 10 min at 90
 
8
 
C and
washed again three times with PBS. Sections were then incu-
bated for 30 min at room temperature with affinity-purified, flu-
orescein-conjugated goat F(ab
 
9
 
)
 
2
 
 fragments (H 
 
1 
 
L chain) anti–
mouse IgG, IgM, or C3 (Zymed Labs., Inc.). After washing three
times in PBS, slides were mounted and examined with an Olym-
pus BX50 microscope equipped with epifluorescence using an
Olympus BH2-RFL-T3 mercury lamp and appropriate optics.
Crescentic glomerulonephritis were counted in at least 50 glom-
eruli randomly selected in a histologic section from each mouse.
 
Cell Separation and Transfer Experiments.
 
Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 mice
were immunized with C-IV as described above. Splenocyte sus-
pensions from the diseased Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 mice were prepared at
day 56, treated with 0.144 M NH
 
4
 
Cl for 1 min for depletion of
erythrocytes, and then transferred intravenously (2 
 
3
 
 10
 
7
 
 cells per
mouse) to either Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 or wild-type naive mice. Alterna-
tively, splenocytes were separated to B220
 
1
 
 and B220
 
2 
 
cells by
magnetic sorting (B220 MACS
 
®
 
 microbeads; Miltenyi Biotec)
before cell transfer. These recipient mice were then boosted 7 d
later with 150 
 
m
 
g of C-IV in IFA and killed 21 d later.
 
Results and Discussion
 
Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 
 
mice, immunized with bovine C-IV in
CFA and boosted at 2, 4, and 6 wk with antigen in IFA,
developed a GPS-like disease with pulmonary hemorrhage
(Fig. 1) and glomerulonephritis (Fig. 2). Nearly all immu-
nized Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 mice developed pulmonary hemor-
rhage, whereas none of the wild-type controls displayed
evidence of disease (Table I; 22 of 24 [92%] versus 0 of 14
[0%], respectively;
 
 P 
 
, 
 
0.001). The appearance of the dis-
eased lungs (Fig. 1 A) revealed extensive hemorrhage dif-
fusely scattered throughout the organ, in sharp contrast to 
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the results reported in previous attempts to induce GPS in
rats and mice (9–11), in which only regional hemorrhagic
patches were observed. Histopathological examinations of a
diseased lung indicate massive hemorrhage with infiltrating
neutrophils and macrophages (Fig. 1, B–D), whereas lung
samples from wild-type mice were normal (Fig. 1, F and
G). The diseased animals displayed bilateral alveolar hem-
orrhage (data not shown) as well as alveolar capillaritis with
extensive infiltration of neutrophils and macrophages (Fig.
1 D). During this experiment, five of the immunized
Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 mice died of tracheal obstruction caused by
hemoptysis (Table I).
Histopathological examination of the kidneys in immu-
nized Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 animals revealed typical crescentic glom-
erulonephritis and tubulointerstitial nephritis, with infiltra-
tion of neutrophils and multinuclear giant cells and hyaline
droplet degeneration of the tubules in nearly all mice tested
(22 of 24 mice tested [92%]; Fig. 2, A and B), whereas kid-
neys from wild-type mice did not show any pathological
changes (Fig. 2, C and D). Immunized Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 mice
showed higher BUN and serum Cr levels than controls (Ta-
ble I), further confirming the compromised renal function.
In addition, all diseased animals showed proteinuria, with
mean protein levels of 533 mg/dl in the urine (data not
shown). Immunohistochemical staining of glomeruli from
immunized Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 animals with FITC-labeled anti–
mouse IgG demonstrated linear depositions of IgG immune
complexes along the glomerular membrane (Fig. 3 A), in a
Figure 1. Development of pulmonary hemorrhage
in mice with disruption of the FcgRIIB gene immu-
nized with bovine C-IV. A–D are from FcgRIIB2/2
mice, and E–G are from wild-type mice. B–D, F, and
G are representative pictures stained with hematoxylin
and eosin. Original magnifications: B and F, 325; C,
D, and G, 3100.902 Development of Goodpasture’s Syndrome in FcgRIIB-deficient Mice
characteristic ribbon-like pattern, and tubulointerstitial
membrane (Fig. 3 B). In contrast, the deposition of IgG was
hardly detectable in immunized wild-type mice (Fig. 3 C).
Neither IgM nor C3 deposition was detected along the
glomerular basement membranes in the diseased mice (data
not shown).
Histological examination of eye, heart, and liver samples
taken from immunized FcgRIIB2/2 animals at necropsy did
not reveal any evidence of inflammatory disease (data not
shown), confirming that the disease process evident in the
susceptible animals was not the result of a diffuse systemic
inflammatory process. However, the possibility that subclin-
ical autoimmune infiltration of other organs (e.g., gut, cen-
tral nervous system) occurs has not been ruled out. In the
absence of bovine C-IV immunization, FcgRIIB2/2 mice
do not develop any abnormalities in pulmonary and renal
function (data not shown), indicating the necessity of an in-
ductive stimulus to trigger disease in this susceptible back-
ground. The identification of FcgRIIB as a susceptibility
factor in GPS and the ability to induce disease upon immu-
nization with bovine C-IV offers the opportunity to investi-
gate other presumptive triggers in the RIIB2/2 mouse, such
as toxic oxygen, hydrocarbons, or viruses, all of which have
been suggested as possible inducers of human GPS (16).
The pulmonary and renal lesions of GPS are attributed to
anti–glomerular basement membrane antibodies, which bind
to common antigenic sites in the lung and kidney and acti-
vate inflammatory effector responses. Consistent with this
Figure 2. Development of
glomerular changes in mice with
disruption of FcgRIIB. Histo-
logical findings of the kidney
stained with PAS after immuni-
zation with C-IV in FcgRIIB2/2
(A and B) and wild-type mice
(C and D). Original magnifica-
tions: A and C, 325; B and D,
3100. Wild-type mice yielded
no distinct findings, but
FcgRIIB2/2 mice showed cres-
centic glomerulonephritis.
Table I. Summary of the Mice Immunized with C-IV
Genotype
Infiltration of 
inflammatory 
cells in lung*
Lung 
hemorrhage‡
Tubulo-
interstitial 
nephritis
Glomerulo-
nephritis
Crescentic 
glomeruli§ 
Mortality 
rate BUN§ Cr§
(%) % (%)  mg/dl mg/dl
FcgRIIB2/2 22/24 (92) 19/24 (79) 22/24 (92)i 22/24 (92)i 33.8 6 25.0 5/24 (21)¶ 45.7 6 16.0 0.15 6 0.06**
Wild type 0/16 (0) 0/16 (0) 0/16 (0) 0/16 (0) 0 0/16 (0) 23.3 6 8.6 0.06 6 0.02**
FcRg2/2 0/14 (0) 0/14 (0) 0/14 (0) 0/14 (0) 0 0/14 (0) 23.4 6 8.6 0.07 6 0.03
C57BL/6 0/7 (0) 0/7 (0) 0/7 (0) 0/7 (0) 0 0/7 (0) 29.2 6 5.7 0.03 6 0.03
*The number of mice showing infiltration of neutrophils or macrophages in the alveolar space.
‡The number of mice showing massive hemorrhage in alveoli in microscopic observations. All 19 mice showing lung hemorrhage had infiltration of
inflammatory cells in the lung.
§Mean 6 SD.
iAll 22 mice showing glomerulonephritis had tubulointerstitial nephritis.
¶Five of the immunized mice died of the tracheal obstruction caused by hemoptysis.
**Statistical analyses were performed using Student’s t test: P , 0.01 between FcgRIIB2/2 and wild-type mice.903 Nakamura et al. Brief Definitive Report
Figure 3. Deposition of IgG along the glom-
erular basement membrane in FcgRIIB2/2
mice. Immunofluorescence staining of the kid-
ney in FcgRIIB2/2 (A and B) and wild-type
mice (C). FcgRIIB2/2 mice show linear depo-
sition of mouse IgG along the glomerular (A)
and tubulointerstitial basement membranes (B),
whereas the deposition of IgG was undetectable
in immunized wild-type mice (C).
Figure 4. Concentration of anti–bovine C-IV and anti–mouse C-IV antibodies in sera from mice immunized with bovine C-IV. Anti–bovine C-IV anti-
body levels of IgG1, IgG2a, IgG2b, IgM, and IgA subclasses (A–E) and anti–mouse C-IV levels of total IgG, IgG1, IgG2a, and IgG2b (F–I) in wild-type (d),
FcgRIIB2/2 (h), and FcRg2/2 (n) mice. Wild-type mice were used as controls for FcgRIIB2/2 mice as described in Materials and Methods. Each point
represents the mean 6 SD. Statistical analysis was performed using Student’s t test between FcgRIIB2/2 and wild-type mice: *P , 0.05 and **P , 0.01.
pathogenic model, the antibody response of FcgRIIB2/2
mice to bovine C-IV immunization is enhanced relative to
wild-type controls, with elevated titers of anti–bovine C-IV
IgG1, IgG2a, IgG2b, and IgM antibodies observed (Fig. 4,
A–D). Anti–C-IV IgA was not detected during the 8-wk
experimental period of this study (Fig. 4 E), despite the re-
cent description of IgAk GPS in humans (17). Importantly,
FcgRIIB2/2 mice, but not wild-type or FcRg2/2 mice,
showed elevated autoantibody responses to mouse C-IV
(Fig. 4, F–H), suggesting that murine GPS depends on the904 Development of Goodpasture’s Syndrome in FcgRIIB-deficient Mice
autoantibody production in this susceptible background. Al-
though this enhanced antibody response may account for
the GPS disease that develops in these animals, it is likely that
contributions from enhanced effector cell responses to depos-
ited anti–C-IV autoantibodies are a significant factor in the
development of disease, as described in the enhanced mac-
rophage responses in immune complex–mediated alveolitis
(18) and in collagen-induced arthritis (12). In support of this
notion, the alveolar and glomerular diseases could be trans-
ferred only to FcgRIIB2/2 animals (five of nine mice tested)
but not to wild-type mice (zero of eight mice tested) by in-
jecting C-IV–sensitized splenocytes from FcgRIIB2/2 mice
into nonsensitized animals. Disease could not be transferred
by injecting either B2201 or B2202 splenocytes from C-IV–
sensitized FcgRIIB2/2 mice into nonsensitized RIIB2/2 mice
(zero of five mice tested), suggesting the additional require-
ment of sensitized T and B cell cooperation in disease devel-
opment (data not shown).
In this study, several differences have been observed be-
tween this animal model and human GPS. First, we found
the lack of C3 deposition in the kidneys (data not shown)
and the absence of anti–C-IV antibodies of the IgA isotype
(Fig. 4 E) as well as the low mortality rate (Table I) in this
model. In human GPS, the deposition of IgM or C3 was de-
tected along the glomerular basement membranes in some
patients (19), and the deposition of IgA was reported in one
patient (17). It remains to be investigated which factor(s) can
induce IgM, C3, or IgA deposition in the murine kidneys in
the present model. Second, untreated GPS in humans carries
a much higher mortality rate; persons with the full-blown
syndrome die within a few months (19), compared with the
mortality rate of 21% at day 56 in the present model (Table
I), although the clinical severity of lung hemorrhage is al-
most the same for diseased animals and human GPS (Fig. 1).
The reason for the differing lifespans of diseased mice and
humans might partially depend on the difference of the resis-
tance to hypoxia caused by alveolar hemorrhage. In our esti-
mation, the surviving animals at day 56 could also be alive at
day 70. Additional immunizations of these surviving animals
with C-IV would increase their mortality rate.
The observation that FcgRIIB deficiency creates a per-
missive immunological environment for the development of
anti–C-IV autoantibodies offers further support for a role for
this receptor in the mechanism of maintaining tolerance.
FcgRIIB inhibits activation responses triggered by cross-
linking of the B cell antigen receptor (BCR), establishing
cellular thresholds for lymphocyte stimulation (20, 21). In
addition, FcgRIIB is capable of triggering apoptosis when it
is cross-linked in the absence of the BCR (22). The activi-
ties associated with FcgRIIB are manifested in the peripheral
lymphoid compartment, during the process of affinity matu-
ration and memory generation in the germinal center (refer-
ence 22 and Tew, J., T. Manser, and J.V. Ravetch, manu-
script submitted for publication). FcgRIIB expression on B
cells is proposed to prevent the activation, proliferation, and
expansion of low-affinity autoreactive cells in the periphery.
Deficiency in FcgRIIB function removes this checkpoint
and thereby contributes to the development of autoimmu-
nity. The data presented here on the role of FcgRIIB in GPS
suggest that alterations in the function or expression of the
FcgRIIB gene could be a susceptibility factor in the patho-
genesis of the human disease. This novel model for GPS of-
fers the opportunity to dissect the etiological mechanisms of
disease development and the identification of agents that trig-
ger autoantibody production in a susceptible background,
thereby offering new insights into the development of new
therapeutic approaches for the treatment of this disease.
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